Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:APVONASDAQ:BCLINASDAQ:BMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.35-7.7%$0.38$0.30▼$3.33$8.17M-1.37169,736 shs415,503 shsAPVOAptevo Therapeutics$4.97+4.2%$13.27$4.30▼$658.60$2.01M5.7774,634 shs111,298 shsBCLIBrainstorm Cell Therapeutics$1.08-2.7%$1.09$0.72▼$8.09$8.57M0.35357,674 shs449,693 shsBMRABiomerica$3.18-6.2%$3.73$1.93▼$10.16$8.10M0.37277,396 shs42,908 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-7.74%-11.68%-15.68%-44.98%-85.97%APVOAptevo Therapeutics+4.19%+1.02%-50.35%-91.03%-99.98%BCLIBrainstorm Cell Therapeutics-2.70%0.00%-14.29%-31.65%-85.60%BMRABiomerica-6.19%0.00%-11.91%-41.85%-32.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.5 of 5 stars3.53.00.00.03.31.70.0APVOAptevo Therapeutics3.1727 of 5 stars3.55.00.00.04.10.00.6BCLIBrainstorm Cell Therapeutics4.4095 of 5 stars3.55.00.04.72.60.80.6BMRABiomerica0.9687 of 5 stars0.05.00.00.02.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.002,198.85% UpsideAPVOAptevo Therapeutics 3.00Buy$219,040.004,407,143.46% UpsideBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,677.78% UpsideBMRABiomerica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APVO, ACXP, BMRA, and BCLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.003/19/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/AAPVOAptevo Therapeutics$3.11M0.65N/AN/A$3.26 per share1.52BCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ABMRABiomerica$5.68M1.43N/AN/A$0.39 per share8.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)APVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-488.93%-152.51%8/14/2025 (Estimated)BCLIBrainstorm Cell Therapeutics-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)BMRABiomerica-$5.98M-$2.32N/A∞N/A-100.52%-90.19%-64.54%N/ALatest APVO, ACXP, BMRA, and BCLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/A4/14/2025Q3 2025BMRABiomericaN/A-$0.48N/A-$0.06N/A$1.12 million3/17/2025Q4 2024ACXPAcurx Pharmaceuticals-$0.18-$0.16+$0.02-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ABMRABiomericaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.801.80APVOAptevo TherapeuticsN/A1.721.72BCLIBrainstorm Cell TherapeuticsN/A0.050.05BMRABiomericaN/A3.172.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%APVOAptevo Therapeutics8.06%BCLIBrainstorm Cell Therapeutics14.33%BMRABiomerica22.28%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals29.60%APVOAptevo Therapeutics0.01%BCLIBrainstorm Cell Therapeutics11.15%BMRABiomerica15.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals323.48 million11.99 millionOptionableAPVOAptevo Therapeutics50405,0001.46 millionNot OptionableBCLIBrainstorm Cell Therapeutics407.94 million5.32 millionOptionableBMRABiomerica602.55 million15.59 millionOptionableAPVO, ACXP, BMRA, and BCLI HeadlinesRecent News About These CompaniesBiomerica's inFoods® IBS Demonstrates Significant Reductions in GI Pain and Bloating in Real-World StudyMay 24, 2025 | nasdaq.comBiomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback SystemMay 22, 2025 | globenewswire.comBiomerica Submits PLA Code Application to Enhance Patient Access to inFoods® IBS Diagnostic TestMay 9, 2025 | nasdaq.comPLA Code Application Filed for inFoods IBS Test - A Key Step Toward ReimbursementMay 7, 2025 | tmcnet.comPLA Code Application Filed for inFoods IBS Test — A Key Step Toward ReimbursementMay 7, 2025 | globenewswire.comBiomerica announces Fortel Ulcer Test approved for sale by UAE MinistryApril 24, 2025 | markets.businessinsider.comUnited Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Detection of H. pylori InfectionApril 23, 2025 | globenewswire.comBiomerica Third Quarter 2025 Earnings: US$0.061 loss per share (vs US$0.11 loss in 3Q 2024)April 18, 2025 | finance.yahoo.comBiomerica Announced 1-for-8 Reverse Stock SplitApril 18, 2025 | nasdaq.comBiomerica, Inc.: Biomerica Announces Reverse Stock SplitApril 18, 2025 | finanznachrichten.deBiomerica Inc trading halted, news pendingApril 18, 2025 | markets.businessinsider.comBiomerica says UAE Ministry of Health approves Fortel Kidney Disease TestApril 18, 2025 | markets.businessinsider.comUnited Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Disease Test for Early Detection of Kidney DamageApril 17, 2025 | markets.businessinsider.comUnited Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Disease Test for Early Detection of Kidney DamageApril 17, 2025 | globenewswire.comBiomerica Stock Slumps After Reverse Stock Split Announcement: Retail’s DisappointedApril 16, 2025 | msn.comBiomerica, Inc.: Biomerica Reports Third Quarter Fiscal 2025 Financial ResultsApril 16, 2025 | finanznachrichten.deBiomerica reports Q3 EPS ($1.20) vs ($1.90) last yearApril 16, 2025 | markets.businessinsider.comBiomerica Announces Reverse Stock SplitApril 16, 2025 | globenewswire.comBiomerica Reports Third Quarter Fiscal 2025 Financial ResultsApril 15, 2025 | markets.businessinsider.comBiomerica Nabs IVDR Certification for Food Intolerance TestsFebruary 26, 2025 | 360dx.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, ACXP, BMRA, and BCLI Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.35 -0.03 (-7.74%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$0.36 +0.01 (+2.01%) As of 06/3/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Aptevo Therapeutics NASDAQ:APVO$4.97 +0.20 (+4.19%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$5.10 +0.13 (+2.52%) As of 06/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Brainstorm Cell Therapeutics NASDAQ:BCLI$1.08 -0.03 (-2.70%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$1.08 -0.01 (-0.46%) As of 06/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Biomerica NASDAQ:BMRA$3.18 -0.21 (-6.19%) Closing price 06/3/2025 03:52 PM EasternExtended Trading$3.35 +0.17 (+5.31%) As of 06/3/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.